DrugDec 13, 2023
Novartis Pharmaceuticals SANDIMMUNE Oral Solution recall — FDA D-0144-2024
Crystallization: bottles of Sandimmune Oral Solution were determined to contain crystals
Class IFDA: OngoingNovartis Pharmaceuticals Corporation
Recall history in this database
Classification mix: Class III: 4, Class II: 1, Class I: 1.
DrugOct 5, 2022
Neoral soft gelatin capsules recall — FDA D-1543-2022
CGMP deviations: Out of specification results obtained during routine stability testing for ethanol content.
Class IIFDA: TerminatedNovartis Pharmaceuticals Corporation
DrugJun 15, 2022
Novartis Pharmaceuticals Xiidra recall — FDA D-0985-2022
Failed Impurities/Degradation Specifications.
Class IIIFDA: TerminatedNovartis Pharmaceuticals Corporation
DrugJun 15, 2022
Xiidra recall — FDA D-0984-2022
Failed Impurities/Degradation Specifications.
Class IIIFDA: TerminatedNovartis Pharmaceuticals Corporation
DrugJun 15, 2022
Novartis Pharmaceuticals Xiidra recall — FDA D-0983-2022
Failed Impurities/Degradation Specifications.
Class IIIFDA: TerminatedNovartis Pharmaceuticals Corporation
DrugJun 15, 2022
Xiidra recall — FDA D-0982-2022
Failed Impurities/Degradation Specifications.
Class IIIFDA: TerminatedNovartis Pharmaceuticals Corporation
Understanding this recall history
This page summarizes recall records in which the official source identifies Novartis Pharmaceuticals Corporation as the recalling firm or manufacturer. The number of records should not be treated as a safety rating or a measure of company size, because recall counts depend on product mix, reporting periods and how government records are organized.
Compare the dates, categories and classifications together rather than relying on the total alone. Open an individual record for the recalled product, reason, distribution details and current instructions available from the source.